Advanced in Ewing Sarcoma

Dr. Jacob S. Thomas

Oncology | Hematology Oncology
USC Care Medical Group Inc
1441 Eastlake Ave, Suite 2424, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Ewing Sarcoma
USC Care Medical Group Inc
1441 Eastlake Ave, Suite 2424, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jacob Thomas is an Oncologist and a Hematologist Oncology provider in Los Angeles, California. Dr. Thomas is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Squamous Cell Skin Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Non-Small Cell Lung Cancer (NSCLC).

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Los Angeles General Medical Center
Keck Hospital Of USC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

USC CARE MEDICAL GROUP INC
1441 Eastlake Ave, Suite 2424, Los Angeles, CA 90089
Other Locations
USC CARE MEDICAL GROUP INC
1520 San Pablo St, Fl 4, Los Angeles, CA 90033
USC CARE MEDICAL GROUP INC
1500 San Pablo St, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Enrollment Status: Recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: KIN-2787
Study Phase: Phase 1
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Ipatasertib, Pembrolizumab
Study Phase: Phase 2
Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study
Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study
Enrollment Status: Suspended
Publish Date: July 14, 2025
Intervention Type: Biological, Procedure
Study Drug: Cemiplimab
Study Phase: Phase 2
Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers
Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Biological
Study Drug: pAc/emm55 pDNA/Polyethylenimine
Study Phase: Phase 1
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 22, 2024
Intervention Type: Drug
Study Drugs: PRS-343, Atezolizumab
Study Phase: Phase 1
A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
Enrollment Status: Suspended
Publish Date: September 22, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Enrollment Status: Terminated
Publish Date: December 06, 2022
Intervention Type: Biological
Study Drug: RPTR-168
Study Phase: Phase 1
View 8 Less Clinical Trials
Similar Doctors
Elite in Ewing Sarcoma
Dr. Sant P. Chawla
Oncology | Hematology
Elite in Ewing Sarcoma
Dr. Sant P. Chawla
Oncology | Hematology
2811 Wilshire Boulevard, Suite 414, 
Santa Monica, CA 
 (15.6 miles away)
310-552-9999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is currently accepting new patients.

Distinguished in Ewing Sarcoma
Dr. James Hu
Oncology | Hematology | Hematology Oncology
Distinguished in Ewing Sarcoma
Dr. James Hu
Oncology | Hematology | Hematology Oncology

USC Care Medical Group Inc

1441 Eastlake Ave, Suite 2424, 
Los Angeles, CA 
 (0.1 miles away)
323-442-2582
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Hu is an Oncologist and a Hematologist in Los Angeles, California. Dr. Hu is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Synovial Sarcoma, and Liposarcoma.

Distinguished in Ewing Sarcoma
Dr. Mark B. Agulnik
Oncology
Distinguished in Ewing Sarcoma
Dr. Mark B. Agulnik
Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (0.2 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Agulnik is an Oncologist in Los Angeles, California. Dr. Agulnik is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Angiosarcoma, Osteotomy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thomas's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 58 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile